ArticleOncoimmunology2014
Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells.
Article in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Advancing immunotherapy via multiple immune cells co-engagement.Frontiers in immunology · 2026Review
- Immunoglobulin GM (γ marker) allotypes and their role in immune response and disease susceptibility.Journal of immunology (Baltimore, Md. : 1950) · 2025Review
- MUC1 and CREB3 are Hub Ferroptosis Suppressors for Nucleus Pulposus and Annulus Fibrosus Degeneration by Integrated Bioinformatics and Experimental Verification.Journal of inflammation research · 2024Article
- Impact of structural modifications of IgG antibodies on effector functions.Frontiers in immunology · 2023Review
- PKC-mediated phosphorylation and activation of the MEK/ERK pathway as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer.Frontiers in endocrinology · 2022Article
- FcγR Binding and ADCC Activity of Human IgG Allotypes.Frontiers in immunology · 2020Article
- Beyond Allotypes: The Influence of Allelic Diversity in Antibody Constant Domains.Frontiers in immunology · 2020Review
- Complement in malaria immunity and vaccines.Immunological reviews · 2020Review
- The Ligands for Human IgG and Their Effector Functions.Antibodies (Basel, Switzerland) · 2019Review
- Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy.Molecules (Basel, Switzerland) · 2018Review
- Prospects from systems serology research.Immunology · 2018Review
- Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination.Frontiers in immunology · 2017Article
- Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.Frontiers in immunology · 2017Article
- Article
- Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage.Journal of translational medicine · 2016Article
- Genetic variants of Fcγ (GM allotypes) and the Fc-mediated effector functions in HIV-1 controllers.Journal of virology · 2014Article
- Immunoglobulin GM Genes, Cytomegalovirus Immunoevasion, and the Risk of Glioma, Neuroblastoma, and Breast Cancer.Frontiers in oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-dependent, cell-mediated cytotoxicity (ADCC) is one of the major mechanisms underlying the clinical efficacy of anticancer monoclonal antibodies (mAbs), such as the mucin 1 (MUC1)-targeting molecule HuHMFG1. IgG antibodies trigger ADCC upon interaction with Fcγ receptors (FcγRs) expressed on the surface of immune effector cells. Polymorphisms affecting FcγRs are known to influence the magnitude of ADCC, but the impact of natural genetic variations in the Fc-coding sequence, γ marker (GM) allotypes, has not been adequately investigated. Using an ADCC inhibition assay, we demonstrate that IgG1 antibodies of the 3+, 1-, 2- GM allotype block almost all valine-containing FcγRIIIa receptors expressed by natural killer (NK) cells, inhibiting by 93% their ability to mediate HuHMFG1-dependent ADCC against DU145 prostate cancer cells. Of note, the ADCC-inhibitory effect of the same IgG1 molecules was significantly reduced when NK cells expressed phenylalanine-containing FcγRIIIa (93% vs. 50%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.